<p>Orchestra BioMed（納斯達克股票代碼：OBIO - 獲取免費報告）在週二發佈給客户和投資者的研究報告中，B. Riley Financial 的股票研究人員將其目標價格從 12.00 美元下調至 10.00 美元，Benzinga 報道。該公司目前對該股票給予 “買入” 評級。B. Riley Financial 的目標價格意味着該公司當前價格有 148.45% 的潛在上漲空間。</p>
<p>獲取 <strong>Orchestra BioMed</strong> 的提醒：</p>
<p>其他一些研究公司也最近對 OBIO 發表了看法。HC Wainwright 在 5 月 14 日的報告中重申了 “買入” 評級，並將 Orchestra BioMed 的目標價格設定為 10.00 美元。Weiss Ratings 在 4 月 21 日的報告中將 Orchestra BioMed 的評級從 “賣出（d-）” 下調至 “賣出（e+）”。巴克萊在 5 月 13 日的報告中將 Orchestra BioMed 的目標價格從 12.00 美元上調至 13.00 美元，並給予該公司 “超配” 評級。Chardan Capital 在 3 月 12 日的報告中重申了 “買入” 評級，並將 Orchestra BioMed 的目標價格設定為 20.00 美元。最後，華爾街 Zen 在週六的報告中將 Orchestra BioMed 的評級從 “持有” 下調至 “賣出”。五位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票的平均評級為 “適度買入”，共識目標價格為 13.60 美元。</p>
<p><strong>獲取我們最新的 Orchestra BioMed 股票報告</strong></p>
<h2>Orchestra BioMed 股票上漲 1.1%</h2>
<p>在週二的午盤交易中，OBIO 的股票上漲了 0.05 美元，達到 4.03 美元。該公司的股票交易量為 462,734 股，而其平均交易量為 215,212 股。該公司的 50 日移動平均線為 4.28 美元，200 日移動平均線為 4.27 美元。公司的市值為 2.4102 億美元，市盈率為-4.15，貝塔值為 0.52。Orchestra BioMed 的 1 年最低價為 2.20 美元，1 年最高價為 5.42 美元。該公司的速動比率為 7.01，流動比率為 7.03，債務與股本比率為 0.35。</p>
<p>Orchestra BioMed（納斯達克股票代碼：OBIO - 獲取免費報告）在 5 月 12 日最後發佈了其財報。該公司報告每股收益（EPS）為-0.33 美元，超出分析師的共識預期（-0.40 美元）0.07 美元。Orchestra BioMed 的股本回報率為-157.46%，淨利潤率為-166.96%。該公司在本季度的收入為 11 萬美元，而分析師預期為 92 萬美元。作為一個整體，分析師預測 Orchestra BioMed 在當前財政年度將發佈-1.62 的每股收益。</p>
<h2>Orchestra BioMed 的內部買賣</h2>
<p>在其他 Orchestra BioMed 的新聞中，董事 Jason Aryeh 在 5 月 15 日的交易中購買了 8,971 股該公司的股票。該股票的平均購買價格為每股 3.90 美元，總交易額為 34,986.90 美元。交易後，該董事持有 117,453 股該公司的股票，價值約為 458,066.70 美元。此次交易使其持股增加了 8.27%。該購買在向證券交易委員會提交的文件中披露，文件可在此鏈接查看。此外，內部人士 David P. Hochman 在 3 月 13 日的交易中購買了 10,000 股該公司的股票。該股票的平均購買價格為每股 4.29 美元，總價值為 42,900.00 美元。交易後，該內部人士直接持有 1,086,467 股該公司的股票，價值約為 4,660,943.43 美元。此次交易使其持股增加了 0.93%。該購買的 SEC 文件提供了更多信息。在過去 90 天內，內部人士購買了價值 179,337 美元的 43,971 股公司股票。內部人士持有該公司 7.50% 的股份。</p>
<h2>Orchestra BioMed 的機構交易</h2>
<p>機構投資者和對沖基金最近對該公司的持倉進行了調整。Virtu Financial LLC 在第四季度購買了 Orchestra BioMed 的新股份，價值 57,000 美元。Jane Street Group LLC 在第二季度購買了 Orchestra BioMed 的新股份，價值 50,000 美元。XTX Topco Ltd 在第二季度購買了 Orchestra BioMed 的新股份，價值 45,000 美元。Creative Planning 在第二季度購買了 Orchestra BioMed 的新股份，價值 40,000 美元。最後，Bank of America Corp DE 在第一季度將其在 Orchestra BioMed 的持倉增加了 200.7%。Bank of America Corp DE 現在擁有 52,761 股該公司的股票，價值 224,000 美元，此前在上個季度又購買了 35,214 股。機構投資者持有該公司 53.20% 的股份。</p>
<h2>影響 Orchestra BioMed 的主要頭條新聞</h2>
<p>以下是本週影響 Orchestra BioMed 的主要新聞：</p>
<ul>
<li>積極情緒：董事 Eric Fain 以每股 4.13 美元購買了 20,000 股，顯示出管理層的信心，並增加了看漲的內部購買趨勢。SEC 文件</li>
<li>積極情緒：內部人士 David P. Hochman 也以每股 3.77 美元購買了 5,000 股，進一步表明公司內部人士的信心。SEC 文件</li>
<li>積極情緒：HC Wainwright 重申了 “買入” 評級和 “10 美元目標價格”，同時略微上調了 2026 年和 2027 年的短期每股收益預期，這可能會讓投資者放心，華爾街仍然看到有意義的上漲空間。分析師覆蓋</li>
<li>積極情緒：該公司表示管理層將參加 Jefferies 全球醫療保健會議，如果投資者期待有關管道進展或合作的更新，這可能會成為催化劑。會議公告</li>
<li>中性情緒：Orchestra BioMed 最新的財報顯示每股損失小於預期，但收入仍遠低於預期，因此整體報告是混合的。財報</li>
</ul>
<h2>關於 Orchestra BioMed</h2>
<p>（獲取免費報告）</p>
<p>Orchestra BioMed, Inc NASDAQ: OBIO 是一家臨牀階段的生物製藥公司，致力於開發針對炎症、纖維化和腫瘤疾病的靶向療法。該公司的研究重點是新型小分子項目，旨在通過利用專有的前藥和靶向抑制劑平台來解決高未滿足需求的疾病。Orchestra BioMed 的產品線包括主要候選藥物 OBI-3424，這是一種由 AKR1C3 激活的前藥，用於治療特定的實體腫瘤，以及旨在抑制病理性炎症和纖維化的下一代調節劑。</p>
<p>Orchestra BioMed 在北美進行早期和中期臨牀研究，與關鍵意見領袖和學術中心緊密合作，以推進其項目。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Orchestra BioMed 更好</li>
<li>HIVE 利用電力進行 AI 轉型</li>
<li>深入分析 NVIDIA 最新的投資組合動向</li>
<li>Brady Corp 構建了一個巨大的 AI 驅動的突破</li>
<li>為什麼 Home Depot 的拋售可能成為一個巨大的機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Orchestra BioMed 嗎？</h2>
<p>在考慮投資 Orchestra BioMed 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Orchestra BioMed 並不在名單上。</p>
<p>雖然 Orchestra BioMed 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

OBIO

醫藥突破 ETF - ALPS

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

標普生物技術 3 倍做多 - Direxion

標普生物技術 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>B. Riley Financial 將 Orchestra BioMed (NASDAQ:OBIO) 的目標股價從 12.00 美元下調至 10.00 美元，同時維持 “買入” 評級。這個新目標暗示從當前價格來看，潛在上漲幅度為 148.45%。其他分析師的觀點各異，有的重申 “買入” 評級，有的則下調了該股票的評級。目前，OBIO 的股價為 4.03 美元，市值為 2.4102 億美元</p>

<p>Orchestra BioMed (NASDAQ:OBIO - Get Free Report) had its price objective decreased by equities researchers at B. Riley Financial from $12.00 to $10.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. B. Riley Financial's price objective would indicate a potential upside of 148.45% from the company's current price.</p>
<div class="lb-trans"><p>Orchestra BioMed（納斯達克股票代碼：OBIO - 獲取免費報告）在週二發佈給客户和投資者的研究報告中，B. Riley Financial 的股票研究人員將其目標價格從 12.00 美元下調至 10.00 美元，Benzinga 報道。該公司目前對該股票給予 “買入” 評級。B. Riley Financial 的目標價格意味着該公司當前價格有 148.45% 的潛在上漲空間。</p>
</div><p>Get <strong>Orchestra BioMed</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Orchestra BioMed</strong> 的提醒：</p>
</div><p>A number of other research firms also recently weighed in on OBIO. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $10.00 price objective on shares of Orchestra BioMed in a report on Thursday, May 14th. Weiss Ratings downgraded Orchestra BioMed from a &#34;sell (d-)&#34; rating to a &#34;sell (e+)&#34; rating in a report on Tuesday, April 21st. Barclays lifted their price objective on Orchestra BioMed from $12.00 to $13.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, May 13th. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Thursday, March 12th. Finally, Wall Street Zen downgraded Orchestra BioMed from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $13.60.</p>
<div class="lb-trans"><p>其他一些研究公司也最近對 OBIO 發表了看法。HC Wainwright 在 5 月 14 日的報告中重申了 “買入” 評級，並將 Orchestra BioMed 的目標價格設定為 10.00 美元。Weiss Ratings 在 4 月 21 日的報告中將 Orchestra BioMed 的評級從 “賣出（d-）” 下調至 “賣出（e+）”。巴克萊在 5 月 13 日的報告中將 Orchestra BioMed 的目標價格從 12.00 美元上調至 13.00 美元，並給予該公司 “超配” 評級。Chardan Capital 在 3 月 12 日的報告中重申了 “買入” 評級，並將 Orchestra BioMed 的目標價格設定為 20.00 美元。最後，華爾街 Zen 在週六的報告中將 Orchestra BioMed 的評級從 “持有” 下調至 “賣出”。五位股票研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票的平均評級為 “適度買入”，共識目標價格為 13.60 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Orchestra BioMed</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 Orchestra BioMed 股票報告</strong></p>
</div><h2>Orchestra BioMed Stock Up 1.1%</h2>
<div class="lb-trans"><h2>Orchestra BioMed 股票上漲 1.1%</h2>
</div><p>Shares of OBIO traded up $0.05 during mid-day trading on Tuesday, reaching $4.03. The company's stock had a trading volume of 462,734 shares, compared to its average volume of 215,212. The business has a fifty day moving average of $4.28 and a 200 day moving average of $4.27. The company has a market cap of $241.02 million, a price-to-earnings ratio of -4.15 and a beta of 0.52. Orchestra BioMed has a 1 year low of $2.20 and a 1 year high of $5.42. The company has a quick ratio of 7.01, a current ratio of 7.03 and a debt-to-equity ratio of 0.35.</p>
<div class="lb-trans"><p>在週二的午盤交易中，OBIO 的股票上漲了 0.05 美元，達到 4.03 美元。該公司的股票交易量為 462,734 股，而其平均交易量為 215,212 股。該公司的 50 日移動平均線為 4.28 美元，200 日移動平均線為 4.27 美元。公司的市值為 2.4102 億美元，市盈率為-4.15，貝塔值為 0.52。Orchestra BioMed 的 1 年最低價為 2.20 美元，1 年最高價為 5.42 美元。該公司的速動比率為 7.01，流動比率為 7.03，債務與股本比率為 0.35。</p>
</div><p>Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%.The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.92 million. As a group, analysts forecast that Orchestra BioMed will post -1.62 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Orchestra BioMed（納斯達克股票代碼：OBIO - 獲取免費報告）在 5 月 12 日最後發佈了其財報。該公司報告每股收益（EPS）為-0.33 美元，超出分析師的共識預期（-0.40 美元）0.07 美元。Orchestra BioMed 的股本回報率為-157.46%，淨利潤率為-166.96%。該公司在本季度的收入為 11 萬美元，而分析師預期為 92 萬美元。作為一個整體，分析師預測 Orchestra BioMed 在當前財政年度將發佈-1.62 的每股收益。</p>
</div><h2>Insider Buying and Selling at Orchestra BioMed</h2>
<div class="lb-trans"><h2>Orchestra BioMed 的內部買賣</h2>
</div><p>In other Orchestra BioMed news, Director Jason Aryeh bought 8,971 shares of the company's stock in a transaction on Friday, May 15th. The stock was bought at an average price of $3.90 per share, for a total transaction of $34,986.90. Following the transaction, the director owned 117,453 shares of the company's stock, valued at approximately $458,066.70. The trade was a 8.27% increase in their position. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, insider David P. Hochman bought 10,000 shares of the company's stock in a transaction on Friday, March 13th. The shares were acquired at an average price of $4.29 per share, with a total value of $42,900.00. Following the transaction, the insider directly owned 1,086,467 shares in the company, valued at approximately $4,660,943.43. The trade was a 0.93% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders acquired 43,971 shares of company stock worth $179,337. Insiders own 7.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Orchestra BioMed 的新聞中，董事 Jason Aryeh 在 5 月 15 日的交易中購買了 8,971 股該公司的股票。該股票的平均購買價格為每股 3.90 美元，總交易額為 34,986.90 美元。交易後，該董事持有 117,453 股該公司的股票，價值約為 458,066.70 美元。此次交易使其持股增加了 8.27%。該購買在向證券交易委員會提交的文件中披露，文件可在此鏈接查看。此外，內部人士 David P. Hochman 在 3 月 13 日的交易中購買了 10,000 股該公司的股票。該股票的平均購買價格為每股 4.29 美元，總價值為 42,900.00 美元。交易後，該內部人士直接持有 1,086,467 股該公司的股票，價值約為 4,660,943.43 美元。此次交易使其持股增加了 0.93%。該購買的 SEC 文件提供了更多信息。在過去 90 天內，內部人士購買了價值 179,337 美元的 43,971 股公司股票。內部人士持有該公司 7.50% 的股份。</p>
</div><h2>Institutional Trading of Orchestra BioMed</h2>
<div class="lb-trans"><h2>Orchestra BioMed 的機構交易</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC bought a new stake in shares of Orchestra BioMed in the 4th quarter valued at $57,000. Jane Street Group LLC bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at $50,000. XTX Topco Ltd bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at $45,000. Creative Planning bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at $40,000. Finally, Bank of America Corp DE increased its position in shares of Orchestra BioMed by 200.7% in the 1st quarter. Bank of America Corp DE now owns 52,761 shares of the company's stock valued at $224,000 after buying an additional 35,214 shares in the last quarter. Institutional investors own 53.20% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近對該公司的持倉進行了調整。Virtu Financial LLC 在第四季度購買了 Orchestra BioMed 的新股份，價值 57,000 美元。Jane Street Group LLC 在第二季度購買了 Orchestra BioMed 的新股份，價值 50,000 美元。XTX Topco Ltd 在第二季度購買了 Orchestra BioMed 的新股份，價值 45,000 美元。Creative Planning 在第二季度購買了 Orchestra BioMed 的新股份，價值 40,000 美元。最後，Bank of America Corp DE 在第一季度將其在 Orchestra BioMed 的持倉增加了 200.7%。Bank of America Corp DE 現在擁有 52,761 股該公司的股票，價值 224,000 美元，此前在上個季度又購買了 35,214 股。機構投資者持有該公司 53.20% 的股份。</p>
</div><h2>Key Headlines Impacting Orchestra BioMed</h2>
<div class="lb-trans"><h2>影響 Orchestra BioMed 的主要頭條新聞</h2>
</div><p>Here are the key news stories impacting Orchestra BioMed this week:</p>
<div class="lb-trans"><p>以下是本週影響 Orchestra BioMed 的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: Director Eric Fain bought 20,000 shares at $4.13 per share, signaling confidence from management and adding to the bullish insider-buying trend. SEC filing</li>
<li>Positive Sentiment: Insider David P. Hochman also purchased 5,000 shares at $3.77, adding another vote of confidence from a company insider. SEC filing</li>
<li>Positive Sentiment: HC Wainwright reiterated a <strong>Buy</strong> rating and <strong>$10 price target</strong>, while slightly raising near-term EPS estimates for 2026 and 2027, which may reassure investors that Wall Street still sees meaningful upside. Analyst coverage</li>
<li>Positive Sentiment: The company said management will participate in the Jefferies Global Healthcare Conference, which could provide a catalyst if investors look for updates on pipeline progress or partnerships. Conference announcement</li>
<li>Neutral Sentiment: Orchestra BioMed’s latest earnings showed a smaller-than-expected loss per share, but revenue remained well below estimates, so the report was mixed overall. Earnings report</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：董事 Eric Fain 以每股 4.13 美元購買了 20,000 股，顯示出管理層的信心，並增加了看漲的內部購買趨勢。SEC 文件</li>
<li>積極情緒：內部人士 David P. Hochman 也以每股 3.77 美元購買了 5,000 股，進一步表明公司內部人士的信心。SEC 文件</li>
<li>積極情緒：HC Wainwright 重申了 “買入” 評級和 “10 美元目標價格”，同時略微上調了 2026 年和 2027 年的短期每股收益預期，這可能會讓投資者放心，華爾街仍然看到有意義的上漲空間。分析師覆蓋</li>
<li>積極情緒：該公司表示管理層將參加 Jefferies 全球醫療保健會議，如果投資者期待有關管道進展或合作的更新，這可能會成為催化劑。會議公告</li>
<li>中性情緒：Orchestra BioMed 最新的財報顯示每股損失小於預期，但收入仍遠低於預期，因此整體報告是混合的。財報</li>
</ul>
</div><h2>About Orchestra BioMed</h2>
<div class="lb-trans"><h2>關於 Orchestra BioMed</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.</p>
<div class="lb-trans"><p>Orchestra BioMed, Inc NASDAQ: OBIO 是一家臨牀階段的生物製藥公司，致力於開發針對炎症、纖維化和腫瘤疾病的靶向療法。該公司的研究重點是新型小分子項目，旨在通過利用專有的前藥和靶向抑制劑平台來解決高未滿足需求的疾病。Orchestra BioMed 的產品線包括主要候選藥物 OBI-3424，這是一種由 AKR1C3 激活的前藥，用於治療特定的實體腫瘤，以及旨在抑制病理性炎症和纖維化的下一代調節劑。</p>
</div><p>Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.</p>
<div class="lb-trans"><p>Orchestra BioMed 在北美進行早期和中期臨牀研究，與關鍵意見領袖和學術中心緊密合作，以推進其項目。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Orchestra BioMed</li>
<li>HIVE Weaponizes Power for an AI Pivot</li>
<li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li>
<li>Brady Corp Wires Up a Massive AI-Powered Breakout</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Orchestra BioMed 更好</li>
<li>HIVE 利用電力進行 AI 轉型</li>
<li>深入分析 NVIDIA 最新的投資組合動向</li>
<li>Brady Corp 構建了一個巨大的 AI 驅動的突破</li>
<li>為什麼 Home Depot 的拋售可能成為一個巨大的機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=OBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Orchestra BioMed Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Orchestra BioMed 嗎？</h2>
</div><p>Before you consider Orchestra BioMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Orchestra BioMed 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Orchestra BioMed 並不在名單上。</p>
</div><p>While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Orchestra BioMed 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Orchestra BioMed (NASDAQ:OBIO) Given New $10.00 Price Target at B. Riley Financial

Market Beat

Orchestra BioMed

巴克萊銀行

Virtu Finc

美國銀行

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存託優先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Orchestra BioMed（NASDAQ:OBIO）被 B. Riley Financial 設定了新的目標價為 10.00 美元